U.S. President Joe Biden will commemorate the one-year anniversary of signing the Inflation Reduction Act, his pivotal clean energy legislation, by spearheading an initiative to enhance Americans’ understanding of its purpose and impact.
The climate-centric bill channels billions of dollars into tax credits, facilitating consumer purchases of electric vehicles and fostering renewable energy production by companies. Biden’s aim is to steer the formidable U.S. power sector towards decarbonization. Furthermore, the legislation assists seniors in covering prescription drug expenses, expands certain facets of Obamacare, and allocates financial responsibilities to affluent individuals and corporations.
A year since its enactment, the legislation colloquially referred to as the IRA, akin to many substantial U.S. statutes, has garnered mixed reviews. Simultaneously, a significant number of Americans, even those supportive of Biden, remain uninformed about its specifics, according to opinion polls conducted by Reuters.
President Biden, a Democrat, will address the bill from the White House on Wednesday afternoon, joined by U.S. lawmakers who contributed to its passage. The administration has shared online testimonials from citizens highlighting how the legislation has positively impacted them.
Among the promises put forth by Biden and Democrats regarding the IRA bill were claims of reducing the U.S. budget deficit by $300 billion over a decade. This would be achieved by imposing a 15% minimum corporate tax on affluent corporations, bolstering the audit workforce to scrutinize wealthy individuals’ tax returns, and empowering the federal government to negotiate drug prices with pharmaceutical firms.
However, the tax credits included in the legislation have gained significant popularity among companies, generating job growth, environmental advantages, and an elevated price tag. Meanwhile, Republicans utilized this year’s budget standoff to curtail some of Biden’s endeavors to enhance tax revenue from affluent Americans. Additionally, pharmaceutical companies have taken legal action against the administration in response to its drug price negotiation plans.
